Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Exelixis, Inc. - Common Stock (NQ:EXEL)

39.14 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Exelixis Q2 Revenue Falls 11 Percent
Via The Motley Fool
Topics Earnings Intellectual Property
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday?
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
Peering Into Exelixis's Recent Short Interest
 
Via Benzinga
Peering Into Exelixis's Recent Short Interest
 
Via Benzinga
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
EXELIXIS INC (NASDAQ:EXEL): A Prime Example of Affordable Growth in Biotech
EXELIXIS (NASDAQ:EXEL) offers strong growth, fair valuation, and financial health, fitting the "Affordable Growth" strategy with high scores in profitability and low bankruptcy risk. 
Via Chartmill
Topics Bankruptcy
Uncovering Potential: Exelixis's Earnings Preview
 
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL): A Strong Growth Stock with Bullish Technical Breakout Potential
EXELIXIS INC (EXEL) combines strong growth fundamentals—high profitability, solid financials, and rising revenue—with bullish technical signals, making it a promising breakout candidate for investors. 
Via Chartmill
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Earnings Scheduled For July 28, 2025
 
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL) – A High-Growth Momentum Stock with Strong Technical Setup
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors and breakout traders. 
Via Chartmill
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner
Via The Motley Fool
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in High-Growth Oncology Stocks
EXELIXIS (NASDAQ:EXEL) shows strong technical and fundamental growth, meeting Minervini’s Trend Template criteria with high earnings momentum and a bullish chart setup. 
Via Chartmill
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note. 
Via The Motley Fool
Topics Intellectual Property
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025
From Exelixis, Inc.
Via Business Wire
Assessing Exelixis: Insights From 12 Financial Analysts
 
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors
EXELIXIS INC (NASDAQ:EXEL) shows strong growth, profitability, and financial health, making it a standout for investors following Louis Navellier’s strategy. With high earnings surprises and... 
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation
EXELIXIS INC (NASDAQ:EXEL) offers strong growth potential at a reasonable valuation, backed by solid profitability and a debt-free balance sheet. A compelling pick for growth investors. 
Via Chartmill
2 Stocks to Buy With Less Than $50
Via The Motley Fool
Topics Intellectual Property
EXELIXIS INC (NASDAQ:EXEL) - An Undervalued Biotech Stock With Strong Fundamentals
EXELIXIS (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, zero debt, and robust growth prospects, making it a candidate for value investors. 
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Technical Breakout Potential
EXELIXIS (NASDAQ:EXEL) is a strong growth stock with breakout potential, backed by robust earnings, revenue growth, and a healthy technical setup. 
Via Chartmill
3 No-Brainer Stocks to Buy for Under $100 Right Now
Via The Motley Fool
Topics Intellectual Property
EXELIXIS INC (NASDAQ:EXEL) – A High Growth Momentum Stock with Strong Technical Setup
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors. The stock is consolidating with clear support... 
Via Chartmill
This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday
 
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in Growth and Momentum Investing
EXELIXIS INC (NASDAQ:EXEL) shows strong growth momentum and meets Minervini’s trend criteria, making it a stock to watch for high-growth investors. 
Via Chartmill
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug
CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug. 
Via Investor's Business Daily
Kroger Posts Better-Than-Expected Earnings, Joins Couchbase, CarMax And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars
Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety concerns reported. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.